Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities | Haematologica

Peter Valent

首页> 外文期刊>Haematologica >Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities | Haematologica

【24h】

Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities | Haematologica

机译：与使用二线BCR / ABL酪氨酸激酶抑制剂相关的严重不良事件：合并症患者中优先发生血液学

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Haematologica》 |2011年第10期|共3页
作者
Peter Valent;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia | Haematologica [J] . Thomas Ernst, Jana Hoffmann, Philipp Erben, Haematologica . 2008,第9期

机译：慢性粒细胞白血病患者中，ABL单核苷酸多态性可能会伪装成与酪氨酸激酶抑制剂耐药相关的BCR-ABL突变|血液学
2. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC? [J] . Soverini S, Rosti G, Iacobucci I, The oncologist . 2011,第6期

机译：在具有Bcr-Abl激酶结构域突变的依马替尼耐药的慢性粒细胞白血病患者中，选择最佳的二线酪氨酸激酶抑制剂：IC的可靠性如何？
3. Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? [J] . Gianantonio Rosti, Giovanni Martinelli, Ilaria Iacobucci, The oncologist . 2011,第6期

机译：在具有Bcr-Abl激酶结构域突变的伊马替尼耐药的慢性粒细胞白血病患者中选择最佳的二线酪氨酸激酶抑制剂：IC50的可靠性如何？
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. Investigating allosteric regulation of ABL and BCR-ABL kinases: Implications for small molecule inhibitors [D] . Panjarian, Shoghag B. 2012

机译：研究ABL和BCR-ABL激酶的变构调节：对小分子抑制剂的影响
6. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities [O] . Peter Valent 2011

机译：与使用二线BCR / ABL酪氨酸激酶抑制剂相关的严重不良事件：合并症患者中优先发生
7. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities [O] . Valent, Peter 2011

机译：与使用二线BCR / ABL酪氨酸激酶抑制剂相关的严重不良事件：合并症患者中优先发生

Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities | Haematologica

著录项

相似文献

相关主题

期刊订阅